Chengdu Biocity
VC Fund
Chengdu Biocity is an investment firm.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chengdu Biocity invests in
Stages Chengdu Biocity invests in
Countries Chengdu Biocity invests in
Investment Focus
Industry
- Medical 5 (83%)
- Pharmaceutical 4 (67%)
- Biotechnology 3 (50%)
- Health Care 2 (33%)
- Biopharma 1 (17%)
Stage
- Series A 3 (50%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series E 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Joyo Pharma
|
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases. | $14M / Series C / Jun 07, 2023 | |
TechnoDerma Medicines
|
TechnoDerma Medicines focuses on the research and development of innovative skin drugs for external use. | Series A / Jan 13, 2023 | |
Xilingyuan Pharmaceutical
|
Xilingyuan Pharmaceutical is a generic drug and innovative drug developer. | $12.6M / Series B / Nov 24, 2022 | |
Zenitar
|
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia. | $16.8M / Series A / Dec 08, 2021 | |
Feitong Bio
|
Feitong Bio platform discovers and develops innovative drugs using monoclonal antibody screening, molecular activity detection. | $15.7M / Series A / Dec 01, 2021 | |
Biostar Technologies
|
Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor smallmolecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level. | $890M / Series E / Nov 26, 2020 |
Co-Investors
CCB International
1 deal together
Chengdu Hi-tech Investment Group
1 deal together
EFung Capital
1 deal together
Hongke Baishi
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chengdu Biocity invest in?
Chengdu Biocity invests primarily in Medical, Pharmaceutical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chengdu Biocity last invest?
The most recent investment recorded for Chengdu Biocity closed in Jun 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
